Stay updated on PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial
Sign up to get notified when there's something new on the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page.

Latest updates to the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2, indicating a minor maintenance update with no observed changes to study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange Detected- Added Revision: v3.4.1 and removed Revision: v3.4.0, indicating a minor version update.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed, indicating a minor update to the page's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedExpanded the Locations section to list study sites across multiple US states (Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New York, Oklahoma, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington) and international sites in Australia (Australian Capital Territory, New South Wales, Queensland, Victoria) and Canada (Ontario, Quebec). The HHS Vulnerability Disclosure link was removed.SummaryDifference2%

- Check91 days agoChange DetectedThe Publications section now notes that publications are automatically filled from PubMed, and the revision tag has been updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedRemoved the general government funding/status banner from the page. The study details, eligibility criteria, and primary outcomes remain unchanged.SummaryDifference0.2%

Stay in the know with updates to PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page.